Learn more how artificial intelligence (AI) is being used to accelerate and enhance drug discovery. Our expert panel will discuss how artificial intelligence is reshaping how drugs are being discovered and the benefits of using AI for drug discovery. Hear from leading experts, including Joel Dudley, Partner at Innovation Endeavors; Doug Chapnick, Founder & CEO of Bioloomics; and Hannah Gordon, Chief Product Officer at Enveda.

This event offers a unique opportunity to delve into the cutting-edge applications of AI in drug discovery and understand how it is driving breakthroughs in healthcare. Don’t miss this chance to engage with industry leaders and learn about the future of AI-driven medical advancements.

Please find more information about the panel members below:

Doug Chapnick, PhD is the Founder and CEO of BioLoomics, Inc., an oncology biotech company that develops antibodies with improved cancer killing properties. With a PhD in Biochemistry from the University of Colorado Boulder, Doug leads BioLoomics in utilizing a closed loop wetlab/AI process to explore massive antibody design space for the idea antibody drug conjugates (ADCs) to kill tumors. His career has been focused on pushing scientists to challenge the status quo and constantly rethink ‘why do we not have cures for our diseases? What are we missing?’

Joel Dudley, PhD is a Partner at Innovation Endeavors, where he invests at the intersection of technology, healthcare, and life sciences. With a BS in Microbiology from Arizona State and an MS and PhD in Biomedical Informatics from Stanford, Joel has served as an Associate Professor at the Icahn School of Medicine. He is also a board member at Think Bioscience, Harmonic Discovery, and Character Biosciences, contributing his expertise in data-driven healthcare innovations.

Hannah Gordon, PhD, MSCI is the Chief Product Officer at Enveda Biosciences, bringing deep expertise in AI-guided drug discovery and translational medicine. With a PhD in Human Genetics and an MS in Clinical Investigation from the University of Utah, Hannah leads teams combining machine learning with rigorous biotech research to develop impactful drug programs. A classically trained molecular biologist, she focuses on translating research into real-world outcomes, driving innovation in the biotech industry with a commitment to scientific rigor and patient outcomes.

Register